# Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.

> **NCT01649271** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 13 (actual)

## Conditions studied

- Breast Neoplasms
- Stomach Neoplasms

## Interventions

- **DRUG:** Herceptin
- **DRUG:** afatinib
- **DRUG:** trastuzumab
- **DRUG:** Herceptin
- **DRUG:** afatinib
- **DRUG:** afatinib

## Key facts

- **NCT ID:** NCT01649271
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07-23
- **Primary completion:** 2016-06-23
- **Final completion:** 2016-06-23
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2025-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01649271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01649271, "Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01649271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*